Framingham Longitudinal Study (USUHS)
Abstract
DoD Cancer Moonshot Program - DoD Framingham DoD’s Cancer Moonshot requirement is a mission of the Murtha Cancer Center (MCC) at USUHS under the authority of a tri-federal Memorandum of Agreement signed July 2016 by the Acting Assistant Secretary of Defense for Health Affairs (DoD), the Under Secretary of Health, Department of Veterans Affairs, Veterans Health Administration (VHA), and the Acting Director of the National Cancer Institute (NIH), for a tri-federal program of Clinical Proteogenomics Cancer Research. DoD’s Cancer Moonshot promotes readiness and mission accomplishment of the active duty service member (ADSM) force, as well as military beneficiaries, retirees, and veterans. There are about 1,000 ADSMs who are stricken with a new cancer diagnosis annually, and MCC serves as the DoD’s Health Affairs-approved Center of Excellence for cancer care and research for these ADSMs. MCC’s mission is to bring translational cancer research to all patients in order to improve their health and mission performance, and to help prevent, screen, detect, and treat cancer; minimize side effects of cancer treatments; and return to duty ADSMs stricken with cancer, as well all other DoD beneficiaries. DoD’s Cancer Moonshot initiative allows for the provision of state-of-the-art molecular analysis of tumors and blood of cancer patients which will result in increased force readiness through more targeted treatment of cancers with fewer side effects, as well as better screening for cancer risk and development.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2024
- Source ID
- 479_0603115DHA_2_0130_PB_2024
Related Documents
- Root: Medical Technology Development
- Child Accomplishment: DoD Cancer Moonshot Program - DoD Framingham Longitudinal Study